A share price of Achieve Life Sciences Inc [ACHV] is currently trading at $2.62, up 1.55%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ACHV shares have gain 2.75% over the last week, with a monthly amount glided 26.57%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Achieve Life Sciences Inc [NASDAQ: ACHV] stock has seen the most recent analyst activity on November 14, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $12. Previously, Raymond James started tracking the stock with Strong Buy rating on September 27, 2024, and set its price target to $20. On May 10, 2023, Maxim Group reiterated its Buy rating and revised its price target to $20 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $23 on June 23, 2021.
Achieve Life Sciences Inc experienced fluctuations in its stock price throughout the past year between $1.84 and $5.31. Currently, Wall Street analysts expect the stock to reach $4.75 within the next 12 months. Achieve Life Sciences Inc [NASDAQ: ACHV] shares were valued at $2.62 at the most recent close of the market. An investor can expect a potential return of 81.3% based on the average ACHV price forecast.
Analyzing the ACHV fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.69, Equity is -1.76 and Total Capital is -1.02. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.97.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Achieve Life Sciences Inc [NASDAQ:ACHV] is 3.51. Also, the Quick Ratio is 3.51, while the Cash Ratio stands at 1.83.
Transactions by insiders
Recent insider trading involved Oki Mark K, Chief Financial Officer, that happened on Mar 17 ’25 when 10000.0 shares were purchased. Chieve Executive Officer, Stewart Richard Alistair completed a deal on Mar 17 ’25 to buy 10000.0 shares.
